Stock 2268 WUXI XDC CAYMAN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials WuXi XDC Cayman Inc.

Equities

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E.
Other stock markets
 23:00:00 20/06/2024 BST 		5-day change 1st Jan Change
17.94 USD +1.36% Intraday chart for WuXi XDC Cayman Inc. +9.66% -43.94%
05-17 Certain Shares of WuXi XDC Cayman Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2024. CI
05-13 WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling DJ

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 34,275 19,987 - -
Enterprise Value (EV) 1 30,230 16,620 16,787 16,394
P/E ratio 112 x 34.2 x 21.6 x 14.9 x
Yield - - - -
Capitalization / Revenue 16.1 x 6.32 x 4.33 x 3.15 x
EV / Revenue 14.2 x 5.26 x 3.64 x 2.58 x
EV / EBITDA 81.2 x 21 x 13.4 x 9.19 x
EV / FCF -154 x -19.1 x -352 x 33.3 x
FCF Yield -0.65% -5.24% -0.28% 3.01%
Price to Book 6.39 x 3.35 x 2.9 x 2.42 x
Nbr of stocks (in thousands) 1,178,446 1,197,604 - -
Reference price 2 29.09 16.69 16.69 16.69
Announcement Date 25/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 2,124 3,160 4,614 6,351
EBITDA 1 - 372.5 793.3 1,249 1,784
EBIT 1 - 343.5 661.1 1,067 1,568
Operating Margin - 16.17% 20.92% 23.12% 24.69%
Earnings before Tax (EBT) 1 - 359.6 710 1,123 1,628
Net income 1 155.7 283.5 575.5 918.3 1,335
Net margin - 13.35% 18.21% 19.9% 21.02%
EPS 2 0.1800 0.2600 0.4873 0.7726 1.119
Free Cash Flow 1 - -196.5 -870.7 -47.67 493
FCF margin - -9.25% -27.55% -1.03% 7.76%
FCF Conversion (EBITDA) - - - - 27.63%
FCF Conversion (Net income) - - - - 36.93%
Dividend per Share 2 - - - - -
Announcement Date 06/11/23 25/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 S2 2024 S1 2024 S2
Net sales 1 1,130 1,392 1,702
EBITDA - - -
EBIT 1 192.4 337.6 423.4
Operating Margin 17.02% 24.25% 24.88%
Earnings before Tax (EBT) 148 - -
Net income 106.3 - -
Net margin 9.41% - -
EPS 0.0800 - -
Dividend per Share - - -
Announcement Date 25/03/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - - - -
Net Cash position 1 - 4,045 3,367 3,201 3,593
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -197 -871 -47.7 493
ROE (net income / shareholders' equity) - 8.18% 10.2% 14.2% 17.5%
ROA (Net income/ Total Assets) - 6.14% 9.45% 12% 15%
Assets 1 - 4,616 6,089 7,671 8,917
Book Value Per Share 2 - 4.550 4.980 5.750 6.890
Cash Flow per Share 2 - 0.3100 0.6000 0.8100 1.220
Capex 1 - 529 1,546 958 471
Capex / Sales - 24.92% 48.92% 20.76% 7.41%
Announcement Date 06/11/23 25/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for WuXi XDC Cayman Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
16.69 CNY
Average target price
28.8 CNY
Spread / Average Target
+72.54%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
WUXI XDC CAYMAN INC. Stock WuXi XDC Cayman Inc.
-43.94% 2.75B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 796B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.51% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.95% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.66% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+3.39% 228B
NOVARTIS AG Stock Novartis AG
+10.75% 214B
AMGEN INC. Stock Amgen Inc.
+6.99% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 2268 Stock
  4. Financials WuXi XDC Cayman Inc.